Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

14.1K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.1K
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

272
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
272
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

15.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.8K
Pharmacovigilance01:19

Pharmacovigilance

983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

112
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
112
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacy staff perception of the suitability of an app-based medication adherence service and strategies for implementation - A Swiss national survey.

Digital health·2026
Same author

Enhancing Discretion and Consistency in Emergency Contraception Counselling: Implementation of a Digital Support Tool in Community Pharmacies.

Pharmacy (Basel, Switzerland)·2026
Same author

Incidence of Naloxone-Use Before and After Implementing Opioid Safety Measures for Patients Hospitalised on General Wards in a Swiss University Hospital.

Drug safety·2026
Same authorSame journal

Population-Based Assessment of Phenoconversion Potential in Switzerland: A Claims Data Study of Key Drug-Metabolizing Enzymes and Transporters.

Pharmacogenomics and personalized medicine·2026
Same author

Biomarker-Based Prediction of OATP1B1 Activity in Clinical Routine-Investigating Coproporphyrins as Markers for Drug-Drug-Gene Interactions.

Clinical pharmacology and therapeutics·2026
Same author

Patient Preferences Towards Plain Language Resources During their Multiple Sclerosis Journey: A Qualitative Interview Study.

The patient·2026

Related Experiment Video

Updated: Sep 9, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data.

Nina L Wittwer1,2, Christoph R Meier1,2,3, Carola A Huber4

  • 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.

Pharmacogenomics and Personalized Medicine
|September 2, 2025
PubMed
Summary

A significant portion of the Swiss population experiences drug interactions involving pharmacogenomic (PGx) medications and enzyme inhibitors/inducers. These interactions, particularly with CYP2D6 and CYP2C19, highlight the need to consider non-genetic factors in PGx testing.

Keywords:
drug-drug interactiondrug-drug-gene interactionphenoconversion

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.1K

Related Experiment Videos

Last Updated: Sep 9, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.1K

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Clinical Pharmacy

Background:

  • Pharmacogenomic (PGx) testing guides drug selection and dosing.
  • Cytochrome P450 enzymes (CYP2C9, CYP2C19, CYP2D6) are crucial for drug metabolism.
  • Drug-drug interactions (DDIs) involving PGx drugs and enzyme modifiers can alter therapeutic outcomes.

Purpose of the Study:

  • To determine the prevalence of interactions between PGx drugs and their metabolic enzyme inhibitors/inducers in the Swiss population.
  • To assess the frequency of concomitant use of PGx drugs with CYP2C9, CYP2C19, and CYP2D6 inhibitors or inducers.

Main Methods:

  • Utilized claims data from a Swiss insurance company (Helsana) between 2017 and 2021.
  • Defined concomitant use based on temporal windows (± 5 or ± 30 days) for PGx drugs and enzyme modifiers.
  • Analyzed data from 894,748 continuously insured individuals.

Main Results:

  • 17.4% to 24.8% of individuals were exposed to potentially interacting drug pairs.
  • 1.5% to 2.2% were exposed to potentially strong interacting drug pairs.
  • Interactions were most common with CYP2D6 and CYP2C19; affected individuals were more likely female, older, and taking more medications.

Conclusions:

  • High prevalence of DDIs involving PGx drugs necessitates consideration of non-genetic factors.
  • Drug-induced phenoconversions can significantly impact PGx test interpretation.
  • Clinical practice should account for these interactions to optimize pharmacotherapy.